More importantly, many PDE4 inhibitors in development are efficacious in animal models of various inflammatory disorders, such as asthma, COPD, psoriasis, inflammatory bowel diseases, rheumatoid arthritis and in clinical trials for asthma and COPD. This evidence concerns the gene PDE4A and asthma.